Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)

Condition:   Carcinoma, Squamous Cell of Head and Neck
Interventions:   Drug: avelumab;   Radiation: radiotherapy;   Drug: cetuximab
Sponsors:   The Netherlands Cancer Institute;   Merck Sharp & Dohme Corp.
Not yet recruiting - verified October 2016

http://ift.tt/2ektglK